This grant will provide support for the Statistics and Data Management Center (SDMC) of the ECOG- ACRIN Cancer Research Group. The SDMC is organized and operated jointly by the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute (DFCI), the Department of Biostatistics at Brown University, the ECOG-ACRIN Medical Research Foundation (EAMRF), and the American College of Radiology (ACR), under the direction of the Group Statisticians. The primary responsibility for data collection and management belongs to the Data Management Center, consisting of EAMRF and ACR. The primary responsibility for study design, monitoring, and analysis, and for overseeing and coordinating SDMC operations, belongs to the Biostatistics Center, consisting of DFCI and Brown University. The primary contact site for grant administration is DFCI. ECOG-ACRIN is a multi-modality group conducting a wide range of studies, including definitive phase III trials of therapeutic interventions, earlier phase studies developing new therapies, studies focused on diagnosis and of advanced imaging methods, investigation of laboratory and imaging based biomarkers, and studies incorporating patient reported outcomes. The SDMC is responsible for all quantitative aspects of EA's activities. Our overall goals are to conduct clinical trials to the highest standards in statistical methods, data management, and regulatory compliance, while continually improving efficiency of all of our processes and systems to optimize the use of our limited resources. Areas of particular focus in this grant include studies incorporating tissue and imaging biomarkers to direct therapy, studies of immunotherapy, studies of de-intensification of therapy to reduce morbidity, studies investigating novel biomarkers, and studies investigating the relationship of biomarkers and therapy in populations defined by race, ethnicity, gender, and age.

Public Health Relevance

The overall purpose of this grant is to provide expertise in statistics and data management to support the research mission of the ECOG-ACRIN Cancer Research Group. Achievement of our objectives will enable ECOG-ACRIN to continue to produce high quality clinical studies that advance the care of cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180794-08
Application #
10116298
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-29
Project End
2025-02-28
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
8
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Ratai, Eva-Maria; Zhang, Zheng; Fink, James et al. (2018) ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. PLoS One 13:e0198548
King, Rebecca L; Nowakowski, Grzegorz S; Witzig, Thomas E et al. (2018) Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J 8:27
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Marcelletti, John F; Sikic, Branimir I; Cripe, Larry D et al. (2018) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom :
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087

Showing the most recent 10 out of 187 publications